Biomedical Technology

C2iTech Limited

🌍 Official Website 🏢 HKSTP Source
62 Potential

Decision Maker

Professor Chi Wai Michael CHAN
mchan@hku.hk
+852 9101 7545
N/A
Raw Description
Our Beliefs | Our mission is to revolutionise healthcare by addressing unmet medical needs with cutting-edge solutions. By leveraging our scientific expertise and advanced technologies, we aim to improve patient outcomes and enhance the effectiveness of respiratory health interventions. | Technology | 1. Cultivation and Cryopreservation of Organoids | C2iTech specialises in cultivating personalised respiratory organoids from non-invasive patient samples. These organoids act as "mini-models" of the respiratory system, enabling: | - Prediction of responses to infections and treatments | - Evaluation of therapy effectiveness | - Assessment of immune defences against respiratory diseases | Our organoids can be cryogenically stored for long-term use, creating a renewable resource for personalised medicine and advancing medical research. With a high success rate in non-invasive sampling, our organoids are invaluable for infectious disease studies and targeted therapeutic development. | 2. Novel Respiratory Drug Screening | Our Novel Respiratory Drug Screening service allows pharmaceutical and biotech firms to test drugs and vaccines using organoids that closely mimic human respiratory tissues. This offers more accurate results, accelerating the development of life-saving treatments. | 3. Respiratory Virus Research Service | C2iTech provides stable ex vivo research models for government agencies and academic institutions studying respiratory viruses. Our customisable models, derived from diverse donor sources, enable research into viral transmission, pathogenesis, and treatment approaches in relevant human tissue contexts. | Future R&D: Organoid Culture Development and Standardisation | We are developing a proprietary culture medium, Culture Medium 1.0, to enhance organoid growth and functionality. This innovation will optimise experimental models for applications ranging from drug testing to disease modelling. | Organoid Platform Standardisation | C2iTech is dedicated to the standardisation of organoid platforms, a critical step toward enhancing the reliability and translatability of organoid models in preclinical research. By partnering with industry leaders such as JingKe Biotech, we aim to establish comprehensive standard operating procedures (SOPs) for organoid cultivation. This initiative will not only ensure uniformity in organoid production but also facilitate the integration of these models into various therapeutic research applications. | The standardisation process will encompass the development of protocols that cover all aspects of organoid culture, including cell sourcing, media formulation, growth conditions, and characterisation methods. By implementing these SOPs, we will create a framework that allows researchers to replicate results across different labs and studies, thereby improving the quality of data generated from organoid models. | Furthermore, our initiative will prepare the organoid platform for preclinical evaluation, ensuring that these models meet regulatory requirements and are suitable for clinical translation. This preparation is vital for fostering collaboration with pharmaceutical companies and research institutions, thereby enhancing the overall impact of organoid technology in drug discovery and personalised medicine. | Consultancy & Training Services | C2iTech offers scientific consultancy and training workshops in organoid research, equipping participants with hands-on experience and industry-recognised credentials to meet the growing demand for personalised healthcare. | Follow Us || Management team: | Chief Executive Officer: Prof CHAN Chi Wai Michael | Chief Operating Officer: Prof POON Lit Man Leo | Senior Advisor: Prof PEIRIS Joseph Sriyal Malik | R&D team: | Chief Scientific Officer: Prof HUI Pui Yan Kenrie | Chief Technical Officer: Dr CHING Hiu Ha Rachel | R&D executive: Dr LI Tak Ho Alex | Technical Officer: Miss HO Wing Chi Taylor | Honorary Pathologist: Prof NICHOLLS John Malcolm | Honorary Business Development Advisor: Dr HO Chi Yung Alfred | Clinical and Overseas Advisors: | Prof TAM KH Paul KH - Vice President, Macau University of Science and Technology | Prof HO CM James - Clinical Associate Professor, at the Department of Medicine, School of Clinical Medicine, HKU | Prof LAU Yu-lung - Chair Professor, Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine | Prof MATTHAY Michael - Professor, School of Medicine University of California | Prof KIM F Carla - Professor, Harvard Medical School, Harvard University | Description | Respiratory diseases, including Acute Lung Injury, Acute Respiratory Distress Syndrome, and chronic conditions like Asthma and Chronic Obstructive Pulmonary Disease, present significant global health challenges. These conditions, exacerbated by viral infections such as H5N1, SARS, MERS, and SARS-CoV-2, lead to high morbidity and mortality rates, severely impacting quality of life and straining healthcare systems. | C2iTech Limited, a spin-off from a prestigious academic institution, is dedicated to transforming respiratory health through innovative technologies. We specialise in personalised organoid cultivation and offer a comprehensive range of services, including organoid cryopreservation, novel respiratory drug screening, and extensive respiratory virus research. Our unique organoid platform enables the standardisation and development of tailored culture media and frozen organoid products. | Our mission is to revolutionize healthcare by addressing unmet medical needs with cutting-edge solutions. By leveraging our scientific expertise and advanced technologies, we aim to improve patient outcomes and enhance the effectiveness of respiratory health interventions.

Strategic Analysis

Executive Brief

C2iTech Limited is a specialized biotechnology firm focused on respiratory health through the cultivation of personalized respiratory organoids ("mini-organs"). They provide critical ex vivo models for drug screening, vaccine testing, and viral pathogenesis studies (e.g., SARS-CoV-2, H5N1). Their business model relies on the precision, standardization, and stability of biological models to replace or augment animal testing and clinical trials.

Strategic Fit & Lead Score

Lead Score: 62/100 (Adjacent Tech / High-Value R&D)

Why this Score? While C2iTech is primarily a biological services company, their "Organoid Platform Standardization" and "Novel Drug Screening" initiatives require advanced sensing and stable interfaces. 6C’s Diamond Technology—specifically Boron-Doped Diamond (BDD) for electrochemical sensing and SCD for bio-compatible interfaces—addresses the primary technical bottleneck in organoid research: the ability to monitor metabolic changes in real-time without sensor fouling or sample contamination.

6C Solutions Proposal

Application Area 6C Solution Technical Value Prop
Real-Time Metabolite Sensing BDD Electrodes Boron-Doped Diamond is chemically inert and resistant to bio-fouling. It allows for the continuous electrochemical detection of neurotransmitters, metabolites, and drug concentrations directly within the organoid culture media without the sensor degrading.
Organoid-on-a-Chip SCD/PCD Windows & Substrates Diamond’s extreme thermal conductivity and optical transparency (UV to Far-IR) enable high-resolution live-cell imaging and Raman spectroscopy of organoids while maintaining precise temperature control at ±0.01 °C.
Biocompatible Scaffolds MPCVD Diamond Coating Direct diamond coating on microfluidic channels or scaffolds provides a 100% biocompatible, non-leaching surface that promotes cell adhesion and prevents the absorption of small drug molecules into the plastic housing.
Cryopreservation Tech PCD Thermal Spreaders Leveraging PCD’s thermal conductivity (>2000 W/mK) to ensure ultra-uniform and rapid heat extraction during organoid cryopreservation, reducing ice crystal formation and improving post-thaw viability.
Advanced Viral Detection BDD Electrochemical Sensors Develop high-sensitivity sensors for viral load detection in culture supernatants, offering a faster, label-free alternative to PCR for routine monitoring in their Virus Research Service.

Engagement Hooks

  • Technical Question: "As you standardize your organoid platforms, how are you currently addressing the 'bio-fouling' of sensors used for real-time monitoring of oxygen, pH, or drug metabolites in the culture media? Would a wide-bandgap, fouling-resistant electrode like Boron-Doped Diamond improve your data longitudinality?"
  • Value Statement: "6C can provide C2iTech with chemically inert, diamond-based sensing interfaces that enable real-time, label-free monitoring of respiratory organoid health, ensuring your standardized platforms deliver the most accurate drug-response data in the industry."